Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds JonesTrading Downgrades Concert Pharma to Hold

JonesTrading Downgrades Concert Pharma to Hold

JonesTrading analyst Sean Kim downgrades Concert Pharma (NASDAQ:CNCE) from Buy to Hold.

byBenzinga Newsdesk

January 20, 2023

1 minute read

JonesTrading analyst Sean Kim downgrades Concert Pharma (NASDAQ:CNCE) from Buy to Hold.

Jefferies Maintains Buy on Netflix, Raises Price Target to $400

By Benzinga Newsdesk

January 20, 7:22 AM

Jefferies analyst Andrew Uerkwitz maintains Netflix (NASDAQ:NFLX) with a Buy and raises the price target from $385 to $400.

NFLX

News

SYLA Technologies Enters Into A “Capital And Business Alliance Agreement” With RIBERESUTE

By Benzinga Newsdesk

January 23, 10:13 AM

SYLA Technologies Co., Ltd. (NASDAQ:SYT) ("SYLA" or "the Company"), operator of the largest membership real estate crowdfunding platform in Japan, Rimawari-kun, today announced that it has entered into a Capital and

SYT

Analyst Ratings

Assessing Independent Bank Gr: Insights From 5 Financial Analysts

By Benzinga Insights

April 1, 11:00 AM

Independent Bank Gr (NASDAQ:IBTX) has been analyzed by 5 analysts in the last three months, revealing a diverse…

IBTX

Analyst Ratings

Analyst Expectations for EverQuote’s Future

By Benzinga Insights

January 19, 1:01 PM

Within the last quarter, EverQuote (NASDAQ:EVER) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat Bearish…

EVER

JonesTrading Downgrades Concert Pharma to Hold

Related Posts

Jefferies Maintains Buy on Netflix, Raises Price Target to $400

SYLA Technologies Enters Into A “Capital And Business Alliance Agreement” With RIBERESUTE

Assessing Independent Bank Gr: Insights From 5 Financial Analysts

Analyst Expectations for EverQuote’s Future